Nothing Special   »   [go: up one dir, main page]

PT3578201T - Métodos e composições para células assassinas naturais - Google Patents

Métodos e composições para células assassinas naturais

Info

Publication number
PT3578201T
PT3578201T PT191756709T PT19175670T PT3578201T PT 3578201 T PT3578201 T PT 3578201T PT 191756709 T PT191756709 T PT 191756709T PT 19175670 T PT19175670 T PT 19175670T PT 3578201 T PT3578201 T PT 3578201T
Authority
PT
Portugal
Prior art keywords
compositions
methods
natural killer
killer cells
cells
Prior art date
Application number
PT191756709T
Other languages
English (en)
Original Assignee
Univ Of Central Florida Research Foundation Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Central Florida Research Foundation Incorporated filed Critical Univ Of Central Florida Research Foundation Incorporated
Publication of PT3578201T publication Critical patent/PT3578201T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT191756709T 2012-06-28 2013-06-28 Métodos e composições para células assassinas naturais PT3578201T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261665591P 2012-06-28 2012-06-28

Publications (1)

Publication Number Publication Date
PT3578201T true PT3578201T (pt) 2023-05-10

Family

ID=49783918

Family Applications (1)

Application Number Title Priority Date Filing Date
PT191756709T PT3578201T (pt) 2012-06-28 2013-06-28 Métodos e composições para células assassinas naturais

Country Status (16)

Country Link
US (5) US9623082B2 (pt)
EP (3) EP4279579A3 (pt)
AU (3) AU2013282353B2 (pt)
CA (1) CA2877968A1 (pt)
DK (1) DK3578201T3 (pt)
ES (1) ES2943932T3 (pt)
FI (1) FI3578201T3 (pt)
HR (1) HRP20230424T1 (pt)
HU (1) HUE061931T2 (pt)
LT (1) LT3578201T (pt)
PL (1) PL3578201T3 (pt)
PT (1) PT3578201T (pt)
RS (1) RS64172B1 (pt)
SG (2) SG10201610915XA (pt)
SI (1) SI3578201T1 (pt)
WO (1) WO2014005072A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP2824112B1 (en) * 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
JP6694875B2 (ja) 2014-05-15 2020-05-20 ナショナル ユニヴァーシティ オブ シンガポール 改変ナチュラルキラー細胞及びその使用
SG11201703397UA (en) 2014-10-27 2017-05-30 Univ Central Florida Res Found Methods and compositions for natural killer cells
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109952369B (zh) * 2016-10-05 2024-03-22 弗罗里达中央大学研究基金会 涉及nk细胞和抗pdl1癌症治疗的方法和组合物
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN110494557A (zh) 2017-03-27 2019-11-22 新加坡国立大学 用于离体扩增和活化自然杀伤细胞的刺激细胞系
MX2019011514A (es) 2017-03-27 2020-01-27 Nat Univ Singapore Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
CN110891584B (zh) * 2017-05-25 2024-02-13 弗罗里达中央大学研究基金会 用于使肿瘤细胞对自然杀伤细胞的杀灭敏感的新型溶瘤病毒
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
SG11202008008UA (en) * 2018-02-21 2020-09-29 Univ Texas Universal antigen presenting cells and uses thereof
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN109627342B (zh) * 2018-12-10 2022-12-06 苏州近岸蛋白质科技股份有限公司 应用于nk细胞培养的蛋白质、培养基配方组合及制备方法
EP3894011A1 (en) 2018-12-11 2021-10-20 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
BR112021013971A2 (pt) * 2019-01-24 2021-11-16 Univ Central Florida Res Found Inc Composições e métodos para estimular células natural killer
CN113646008A (zh) * 2019-01-28 2021-11-12 罗德岛大学理事会 pHLIP®肽介导的细胞表面的表位束缚
US12029793B2 (en) * 2019-01-28 2024-07-09 Yale University pH low insertion peptide targeted delivery of potent cytotoxic compounds
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3935159A1 (en) 2019-03-08 2022-01-12 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
JP2022539019A (ja) * 2019-06-25 2022-09-07 シティ・オブ・ホープ Ｐｄｌ１陽性ｎｋ細胞がん処置
CN112391349B (zh) * 2019-08-19 2023-05-23 刘韬 滋养层细胞株及其制备方法和体外诱导扩增nk细胞的方法
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CN112426438B (zh) * 2019-11-14 2023-12-05 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
CN113646435A (zh) * 2019-12-09 2021-11-12 南克维斯特公司 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆
AU2021205416A1 (en) 2020-01-08 2022-08-25 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
WO2021188974A1 (en) * 2020-03-20 2021-09-23 Orgenesis Inc. Ribonucleases for treating viral infections
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
JP2023526804A (ja) * 2020-06-09 2023-06-23 サムスン ライフ パブリック ウェルフェア ファウンデーション Ｎｋ細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途
WO2022047419A1 (en) 2020-08-31 2022-03-03 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
US20240299542A1 (en) 2021-01-05 2024-09-12 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
KR20240036997A (ko) * 2022-09-14 2024-03-21 재단법인 한국마이크로의료로봇연구원 사이토카인 활성 강화된 자연살해세포 유래 엑소좀의 암 치료용 생물학적 조성물 및 이의 용도
CN117987365B (zh) * 2023-12-27 2024-08-06 常州市第一人民医院 一种裂亡前列腺癌细胞囊泡的工程化改造方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
KR100922809B1 (ko) 1999-05-06 2009-10-21 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
EP1349873B1 (en) * 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation of il-2- and il-15-mediated t cell responses
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030148454A1 (en) * 2001-11-02 2003-08-07 Trustees Of Boston University Virus-free vesicles for delivery of functional membrane bound proteins
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
ES2342606T3 (es) * 2003-08-21 2010-07-09 Lipotek Pty Ltd. Blanco in vivo de celulas dentriticas.
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005070120A2 (en) * 2004-01-09 2005-08-04 Serologicals Investment Company, Inc. Cell culture media
WO2005124346A1 (en) * 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
ES2491118T3 (es) * 2005-11-28 2014-09-05 Zymogenetics, Inc. Antagonistas de IL-21
KR20080090412A (ko) 2005-12-08 2008-10-08 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 생체내 세포 표면 엔지니어링
JP5591712B2 (ja) * 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
WO2010071836A1 (en) * 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2013177187A2 (en) * 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2013175237A1 (en) 2012-05-24 2013-11-28 Ucl Business Plc Composition comprising a cd2 ligation agent and a nkg2d ligation agent

Also Published As

Publication number Publication date
US9623082B2 (en) 2017-04-18
ES2943932T3 (es) 2023-06-16
SG11201408697QA (en) 2015-02-27
EP2866834A4 (en) 2015-12-09
AU2021202439B2 (en) 2024-09-05
US20200138908A1 (en) 2020-05-07
AU2021202439A1 (en) 2021-05-13
EP2866834B1 (en) 2019-05-22
AU2019200525A1 (en) 2019-02-14
LT3578201T (lt) 2023-05-25
AU2019200525B2 (en) 2021-01-21
US20170319659A1 (en) 2017-11-09
US10463715B2 (en) 2019-11-05
AU2013282353A1 (en) 2015-02-12
EP3578201B1 (en) 2023-04-19
WO2014005072A1 (en) 2014-01-03
EP3578201A1 (en) 2019-12-11
AU2013282353B2 (en) 2018-10-25
US20150190471A1 (en) 2015-07-09
US20230321191A1 (en) 2023-10-12
HRP20230424T1 (hr) 2023-07-07
SI3578201T1 (sl) 2023-06-30
CA2877968A1 (en) 2014-01-03
US11617781B2 (en) 2023-04-04
US20190117736A1 (en) 2019-04-25
FI3578201T3 (fi) 2023-05-05
EP2866834A1 (en) 2015-05-06
RS64172B1 (sr) 2023-05-31
US10874715B2 (en) 2020-12-29
DK3578201T3 (da) 2023-05-08
EP4279579A2 (en) 2023-11-22
HUE061931T2 (hu) 2023-09-28
PL3578201T3 (pl) 2023-09-11
SG10201610915XA (en) 2017-02-27
EP4279579A3 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
SG11201408697QA (en) Methods and compositions for natural killer cells
HK1211620A1 (en) Natural killer cells and uses thereof
SG10201705024PA (en) Methods and compositions for separating or enriching cells
EP2836212A4 (en) NOVEL COMPOSITIONS AND METHOD
HK1208631A1 (en) Compositions and methods for immunotherapy
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL230237B (en) Fat Cell Compounds and Methods
EP2680837A4 (en) COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
GB201200458D0 (en) Methods of preparing cells and compositions
IL227529A0 (en) Compounds and methods of cell transplantation
IL229176A0 (en) Preparations of living cells and their uses
HK1205185A1 (en) Methods and composition related to brown adipose-like cells
EP2854530A4 (en) COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY
HK1206970A1 (en) Antigenic compositions and methods
IL250307A0 (en) Pesticide preparations and methods
GB201315350D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
GB201315347D0 (en) Methods and compositions
HK1231520A1 (zh) 改進的基質穩定性組合物和方法
EP2766357A4 (en) MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR
IL239529A0 (en) Preparations and methods for creating improved and different cells and organisms
HK1210436A1 (en) Novel cell compositions and methods
GB201116340D0 (en) Compositions and methods